Tris trial is registered with FDA with number: NCT02909166. The sponsor of the trial is Mika Lehto and it is looking for 70 volunteers for the current phase.
Official trial title:
Role of ALiskiren, a Direct Renin Inhibitor, in Preventing Atrial Fibrillation in Patients With a Pacemaker; RALF. A Double-blind, Randomized, Parallel-group, Single Centre Study